Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While sales of key drugs Vivitrol and Aristada continue to grow rapidly, Alkermes' overall revenue growth came in much weaker than expected. As a result, management dialed back its revenue growth expectations for the full year. However, containment efforts helped the company to beat expectations on the bottom-line.
Data source: Alkermes. GAAP = generally accepted accounting principles.
Image source: Getty Images.
Source: Fool.com
Alkermes plc Stock
€25.40
0.790%
With 17 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 35 € there is a positive potential of 37.8% for Alkermes plc compared to the current price of 25.4 €.
